– Data presentation on spleen volume reduction
in patients with myelofibrosis also accepted for poster discussion
–
SEATTLE, May 1, 2023
/PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a
commercial biopharmaceutical company focused on the development and
commercialization of novel targeted therapies for blood-related
cancers, today announced that two abstracts have been accepted for
presentation at the upcoming 2023 American Society of Clinical
Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL.
Presentation details are as follows:
Title: Spleen volume reduction (SVR) predicts
overall survival (OS) in myelofibrosis (MF) patients on pacritinib
(PAC) but not best available therapy (BAT): PERSIST-2 landmark OS
analysis
Abstract
#: 7018
Presenter: Helen
Ajufo, M.D., Memorial Sloan
Kettering Cancer Center
Session
Title: Hematologic Malignancies—Leukemia,
Myelodysplastic Syndromes, and Allotransplant
Session Date and Time: Monday, June 5, 2023, 8:00
- 11:00 a.m. CT
Location: Hall
A, Poster #148
Poster discussion: In addition
to the poster presentation, Dr. Ajufo will host a poster discussion
session on Monday, June 5, 2023 from
11:30 a.m. – 1:00 p.m. CT in Room E450.
Title: Consistency of pacritinib for spleen and
symptom reduction in patients with myelofibrosis regardless of
cytopenias
Abstract #: 7068
Presenter: Dr. Prithviraj Bose, M.D., The
University of Texas MD Anderson Cancer
Center
Session Title: Hematologic
Malignancies—Leukemia, Myelodysplastic Syndromes,
and Allotransplant
Session Date and Time: Monday,
June 5, 2023, 8:00 - 11:00 a.m.
CT
Location: Hall A, Poster #198
About CTI BioPharma Corp.
CTI BioPharma is a commercial biopharmaceutical company focused
on the development and commercialization of novel targeted
therapies for blood-related cancers that offer a unique benefit to
patients and their healthcare providers. CTI has one FDA-approved
product, VONJO® (pacritinib), a JAK2, ACVR1, and IRAK1 inhibitor,
that spares JAK1. VONJO is approved for the treatment of adults
with intermediate- or high-risk primary or secondary
(post-polycythemia vera or post-essential thrombocythemia)
myelofibrosis with a platelet count below 50 × 109/L.
This indication is approved under FDA accelerated approval based on
spleen volume reduction. Continued approval for this indication may
be contingent upon verification and description of clinical benefit
in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA
study of VONJO in patients with myelofibrosis and severe
thrombocytopenia as a post-marketing requirement. For more
information, please visit www.ctibiopharma.com.
VONJO® is a registered trademark of CTI BioPharma Corp.
Investor Relations and Media Contacts:
Remy Bernarda
Jenny Kobin
invest@ctibiopharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-announces-two-abstracts-accepted-for-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting-301811764.html
SOURCE CTI BioPharma Corp.